fbpx

TCT Meetings 2022- Focus on GVHD

The 2022 Transplantation & Cellular Therapy (TCT) Tandem Meetings from the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) offer the latest innovations, updates, and breakthroughs in graft-versus-host disease (GVHD) research and care. Stay tuned for some of the studies being presented at this outstanding event.

CD34+ Graft Cell Dose in Allogeneic Peripheral Blood Stem Cell Transplantation

Citing that an optimal CD34+ graft cell dose (CD) for allogeneic peripheral blood stem cell transplant (allo-PBSCT) has not...

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil for GVHD Prevention

In an interim analysis presented by Najla El Jurdi, MD, at the Transplantation & Cellular Therapy 2022 Tandem Meetings,...

Minimum Residual Disease and Cytogenetic Persistence Prior to Hematopoietic Cell Transplant

In a poster featured at the Transplantation & Cellular Therapy 2022 Tandem Meetings, researchers examined outcomes in peripheral blood...
Advertisement

Hematology and Oncology News

Curated Journal Abstracts

Advertisement
Advertisement